Valion Bio, Inc.VBIO
ASignal's systematic analysis rates VBIO as Bearish.
Reflects the latest available analysis · analyzed Sep 13, 2026
The case on VBIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI near 40 suggests potential oversold condition
- MACD histogram is positive and increasing, indicating weakening bearish momentum
- Price near Bollinger Lower Band (~1.79) may signal short-term reversal potential
- Strong downtrend confirmed by price below both SMA20 and SMA50
- Negative price momentum and declining MACD (though above signal line)
- Extremely weak fundamentals: negative operating cash flow and free cash flow
- Very high debt-to-equity ratio (4.10x)
- Negative return on equity (-459.52%) and negative return on assets (-57.13%)
- Negative price-to-sales and enterprise value to EBITDA suggest financial distress
See the full verdict on VBIO
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VBIO
Most investors never get a second opinion, let alone several. ASignal runs VBIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.